Spectral AI, Inc., a Dallas-based artificial intelligence company focused on medical diagnostics for wound care, announced it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial performance and operational updates.

The announcement provides investors with the timeline for accessing the company’s latest financial data, which is critical for assessing the progress of its DeepView System in the medical diagnostics sector. Spectral AI aims to revolutionize wound care management by providing physicians with objective assessments of healing potential prior to treatment.

Conference Call Details

Investors interested in participating in the live call can dial into the conference using the following numbers:

In addition to the teleconference, a simultaneous webcast of the financial results call may be accessed online from the Events section of the Investor Relations page on the company’s website.

About Spectral AI

Spectral AI, Inc. is focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The company’s DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential. With algorithm-driven results, the system aims to exceed the current standard of care by providing fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025.

Spectral AI, Inc. will showcase its DeepView System at the 2026 British Burn Association (BBA) Annual Meeting, scheduled for June 17-19, 2026, at Nottingham Trent University in Nottingham, England. The company, focused on artificial intelligence for medical diagnostics in wound care, will display the technology at Stand #22. The system will be the subject of multiple podium and poster presentations during the multidisciplinary conference, which brings together burn care professionals to share clinical experience and research.

The DeepView System recently received De Novo Classification from the U.S. Food and Drug Administration (FDA) in May 2026. It also obtained initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. Spectral AI expects to generate its first commercial sales of the DeepView System by the end of 2026.

Vincent Capone, Chief Executive Officer of Spectral AI, highlighted the significance of the recent FDA approval. He stated that the classification has created significant runway for enhanced long-term shareholder value. The company aims to elevate the profile of its technology among the burn community by sharing data on the efficacy and impact of the DeepView System in burn wound assessment.

DeepView System Specifications

The DeepView System is a non-invasive, predictive medical device that combines multispectral imaging with a proprietary AI algorithm. It assesses the healing potential of areas within burn wounds to inform treatment decisions.

The system provides clinicians with an immediate, data-driven assessment of whether wounds require significant medical intervention. This enables earlier and more informed treatment decisions, with the goal of improving patient outcomes and reducing healthcare costs.